September 30, 2020

Enesi Pharma reports positive results of needle-free PRRS vaccine

UK-based Enesi Pharma has reported positive top-line results from a new study evaluating the immune responses generated by its ImplaVax^®-enabled unit solid-dose formulation of a live attenuated porcine reproductive and respiratory syndrome virus (PRRSV) vaccine.

The study was conducted in collaboration with The Pirbright Institute, a UK-based global centre of research and surveillance of livestock viral diseases.

The study confirmed the utility of ImplaVax to create a solid-dose live virus vaccine that is immunogenic with the potential for enhanced thermal stability. The subcutaneously delivered ImplaVax format generated both neutralising antibodies and T-cell responses comparable to the standard liquid vaccine delivered either subcutaneously or intramuscularly via needle and syringe.

More details of the study and its results will be presented in an upcoming publication.

David Hipkiss, Enesi Pharma CEO, says, "We are very pleased to report these positive top-line results from this successful study conducted in partnership with The Pirbright Institute, which has proven to be an exemplar collaborator. They provide a strong and clear validation for the potential of ImplaVax as applied to modified live virus vaccines across the whole of the vaccine ecosystem.

We believe there is significant opportunity for Enesi and ImplaVax in the growing animal health market, which is forecast to exceed US$16 billion per annum by 2026.

Both livestock and companion animals need to be continually protected from infectious diseases, and ImplaVax offers a needle-free, thermally stable, safe and effective means of administration."